These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 15093864)

  • 21. [Temporal trends in pharmacological therapy in the IN-CHF registry from 1995 to 2005].
    Fabbri G; Gorini M; Maggioni AP; Di Lenarda A;
    G Ital Cardiol (Rome); 2007 Feb; 8(2):102-6. PubMed ID: 17402354
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor blockers on the rate of new-onset diabetes mellitus: a review and pooled analysis.
    McCall KL; Craddock D; Edwards K
    Pharmacotherapy; 2006 Sep; 26(9):1297-306. PubMed ID: 16945052
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antihypertensive and lipid lowering treatment in stroke prevention: current state and future.
    Piechowski-Jóźwiak B; Bogousslavsky J
    Acta Neurol Belg; 2005 Jun; 105(2):57-61. PubMed ID: 16076057
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Diabetes and hypertension, the deadly duet: importance, therapeutic strategy, and selection of drug therapy.
    Deedwania PC
    Cardiol Clin; 2005 May; 23(2):139-52. PubMed ID: 15694743
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hypertension mega-trials with cardiovascular end points: effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
    Kjeldsen SE; Julius S
    Am Heart J; 2004 Nov; 148(5):747-54. PubMed ID: 15523303
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of combination therapy in the treatment of hypertension: focus on valsartan plus amlodipine.
    Ferri C; Croce G; Desideri G
    Adv Ther; 2008 Apr; 25(4):300-20. PubMed ID: 18449492
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Not all antihypertensive agents protect equally well].
    MMW Fortschr Med; 2006 Aug; 148(33-34):52. PubMed ID: 16981390
    [No Abstract]   [Full Text] [Related]  

  • 28. LIFE and SCOPE: what guidance do they offer alongside ALLHAT and ANBP2?
    Nicholls MG
    J Hum Hypertens; 2004 May; 18(5):295-300. PubMed ID: 14739907
    [No Abstract]   [Full Text] [Related]  

  • 29. Managing hypertension using combination therapy.
    Frank J
    Am Fam Physician; 2008 May; 77(9):1279-86. PubMed ID: 18540493
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Angiotensin 2 type 2 receptor activity and ischemic stroke severity.
    Ovbiagele B; Kidwell CS; Starkman S; Selco SL; Rajajee V; Razinia T; Saver JL
    Neurology; 2005 Sep; 65(6):851-4. PubMed ID: 16186522
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Angiotensin receptor blockers and cerebral protection in stroke.
    Thöne-Reineke C; Steckelings UM; Unger T
    J Hypertens Suppl; 2006 Mar; 24(1):S115-21. PubMed ID: 16601564
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of essential hypertension with calcium channel blockers: what is the place of lercanidipine?
    Burnier M; Pruijm M; Wuerzner G
    Expert Opin Drug Metab Toxicol; 2009 Aug; 5(8):981-7. PubMed ID: 19619074
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antihypertensive drugs and fibrinolytic function.
    Fogari R; Zoppi A
    Am J Hypertens; 2006 Dec; 19(12):1293-9. PubMed ID: 17161777
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Possible pathophysiologic mechanisms supporting the superior stroke protection of angiotensin receptor blockers compared to angiotensin-converting enzyme inhibitors: clinical and experimental evidence.
    Chrysant SG
    J Hum Hypertens; 2005 Dec; 19(12):923-31. PubMed ID: 16049519
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Concomitant calcium entry blockade and inhibition of the renin-angiotensin system: a rational and effective means for treating hypertension.
    Gojanovic B; Feihl F; Liaudet L; Waeber B
    J Renin Angiotensin Aldosterone Syst; 2008 Mar; 9(1):1-9. PubMed ID: 18404602
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Blood pressure lowering, not vascular mechanism of action, is the primary determinant of clinical outcome.
    Leenen FH
    Can J Cardiol; 2004 Aug; 20 Suppl B():77B-82B. PubMed ID: 15309209
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Blockade of the renin-angiotensin system by a combination of ACE inhibitors and AT1 receptor antagonists].
    Azizi M
    Rev Prat; 2004 Jun; 54(11):1167-74. PubMed ID: 15496022
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Drug therapy for hypertension in hemodialysis patients.
    Hörl MP; Tepel M
    Minerva Med; 2005 Aug; 96(4):277-85. PubMed ID: 16179894
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Pharmacological hypertension therapy].
    Pedersen OL; Christensen KL; Bang LE; Ibsen H; Schultz-Larsen P
    Ugeskr Laeger; 2009 Jun; 171(24):2022-5. PubMed ID: 19523367
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Current possibilities of ACE inhibitor and ARB combination in arterial hypertension and its complications.
    Kolasinska-Malkowska K; Filipiak KJ; Gwizdala A; Tykarski A
    Expert Rev Cardiovasc Ther; 2008 Jun; 6(5):759-71. PubMed ID: 18510491
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.